Unprecedented lipid lowering seen with PCSK9 inhibitor plus statin: GLASGOV

A new treatment for coronary atherosclerosis that combines a PCSK9 inhibitor with statin therapy has lowered cholesterol levels in high-risk patients to unprecedented levels marking the start of a new era in lipid lowering management say Australian and US researchers. Presenting the findings of the GLASGOV trial at the American Heart Association’s scientific meeting in ...

Already a member?

Login to keep reading.

© 2021 the limbic